South Korea is preparing to introduce a regulated route for abortion medication, a policy change the government says could take effect as early as the first quarter of 2027. Under the plan described by two Korean news outlets, medication could be used for pregnancies of up to nine weeks through medical institutions, with a doctor’s prescription and dispensing in a clinical setting.
The proposal was presented at a National Policy Coordination Meeting on September 16, according to the reports. It follows years of uncertainty after the Constitutional Court found the abortion ban constitutionally incompatible in 2019. The direction is significant, but it is still a plan: product approval, import procedures and the rules for medical delivery must be completed before patients can use the new route.
Medical care would remain at the center
The planned model is not an over-the-counter release. Both reports describe a system in which healthcare providers would assess a patient, prescribe the medicine and dispense it through a medical institution. That design places the policy within ordinary medical care, with responsibility for clinical guidance resting on providers rather than on informal or unregulated channels.
The government’s timetable is tied to regulatory work now under way. One account says a company has applied for an import-product permit for an oral combination medicine, which is being reviewed by the Ministry of Food and Drug Safety. Approval would not itself settle every detail, but it is a necessary condition for the government’s early-2027 target.
For people seeking early abortion care, the proposal could create a formal option that has not been available through a domestic regulatory pathway. For doctors and hospitals, it would establish a clearer set of responsibilities around prescribing, dispensing and patient information. The reports do not indicate that the medication is available today, and they do not describe a final operating rulebook for providers.
The policy also involves several ministries. The Ministry of Gender Equality and Family, the Ministry of Health and Welfare and the food-and-drug regulator were named in the reporting on the government’s proposal. Their involvement reflects the fact that the issue covers healthcare, medication approval and access to services at the same time.
Approval will shape access
The government has framed the change around a medically supervised pathway for early pregnancies. The account from Kyunghyang Shinmun says use would be limited to pregnancies of up to 63 days, while the Maeil Shinmun report says officials are pursuing the plan after the 2019 court decision. Those details give the proposal a narrower and more specific shape than a broad political declaration.
Whether the target date holds will depend on the approval process, import arrangements and the guidance eventually issued to medical institutions. Korea has now signaled a major policy direction on abortion medication, but patients and providers will need those administrative decisions to turn the announcement into a functioning service.